Global Targeted Drugs for Neurodegenerative Diseases Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Targeted Drugs for Neurodegenerative Diseases market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global Targeted Drugs for Neurodegenerative Diseases market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Global Targeted Drugs for Neurodegenerative Diseases market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Targeted Drugs for Neurodegenerative Diseases market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Targeted Drugs for Neurodegenerative Diseases market shares of main players, in revenue ($ Million), 2021-2026
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Chapter 2, to profile the top players of Targeted Drugs for Neurodegenerative Diseases, with revenue, gross margin, and global market share of Targeted Drugs for Neurodegenerative Diseases from 2021 to 2026.
Chapter 3, the Targeted Drugs for Neurodegenerative Diseases competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Targeted Drugs for Neurodegenerative Diseases market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Targeted Drugs for Neurodegenerative Diseases.
Chapter 13, to describe Targeted Drugs for Neurodegenerative Diseases research findings and conclusion.
This report is a detailed and comprehensive analysis for global Targeted Drugs for Neurodegenerative Diseases market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Targeted Drugs for Neurodegenerative Diseases market size and forecasts, in consumption value ($ Million), 2021-2032Global Targeted Drugs for Neurodegenerative Diseases market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Targeted Drugs for Neurodegenerative Diseases market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Targeted Drugs for Neurodegenerative Diseases market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Targeted Drugs for Neurodegenerative Diseases
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Targeted Drugs for Neurodegenerative Diseases market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.Market segment by Type
- Injection
- Oral
Market segment by Application
- Parkinson's Disease (PD)
- Alzheimer's Disease (AD)
- Huntington's Disease (HD)
- Tardive Dyskinesia (TD)
- Multiple Sclerosis (MS)
Market segment by players, this report covers
- Acadia Pharmaceuticals Inc.
- Kyowa Kirin
- Supernus Pharmaceuticals
- UCB
- Sumitomo Pharma
- Biogen
- Eisai Inc.
- Eli Lilly
- Green Valley
- NOVARTIS
- Bristol-Myers Squibb
- Janssen
- Sanofi
- Roche
- Neurocrine
- Lundbeck
- Teva
Market segment by regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
- South America (Brazil, Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Targeted Drugs for Neurodegenerative Diseases product scope, market overview, market estimation caveats and base year.Chapter 2, to profile the top players of Targeted Drugs for Neurodegenerative Diseases, with revenue, gross margin, and global market share of Targeted Drugs for Neurodegenerative Diseases from 2021 to 2026.
Chapter 3, the Targeted Drugs for Neurodegenerative Diseases competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Targeted Drugs for Neurodegenerative Diseases market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Targeted Drugs for Neurodegenerative Diseases.
Chapter 13, to describe Targeted Drugs for Neurodegenerative Diseases research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Targeted Drugs for Neurodegenerative Diseases by Type
1.3.1 Overview: Global Targeted Drugs for Neurodegenerative Diseases Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Type in 2025
1.3.3 Injection
1.3.4 Oral
1.4 Global Targeted Drugs for Neurodegenerative Diseases Market by Application
1.4.1 Overview: Global Targeted Drugs for Neurodegenerative Diseases Market Size by Application: 2021 Versus 2025 Versus 2032
1.4.2 Parkinson's Disease (PD)
1.4.3 Alzheimer's Disease (AD)
1.4.4 Huntington's Disease (HD)
1.4.5 Tardive Dyskinesia (TD)
1.4.6 Multiple Sclerosis (MS)
1.5 Global Targeted Drugs for Neurodegenerative Diseases Market Size & Forecast
1.6 Global Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast by Region
1.6.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region: 2021 VS 2025 VS 2032
1.6.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region, (2021-2032)
1.6.3 North America Targeted Drugs for Neurodegenerative Diseases Market Size and Prospect (2021-2032)
1.6.4 Europe Targeted Drugs for Neurodegenerative Diseases Market Size and Prospect (2021-2032)
1.6.5 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size and Prospect (2021-2032)
1.6.6 South America Targeted Drugs for Neurodegenerative Diseases Market Size and Prospect (2021-2032)
1.6.7 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Acadia Pharmaceuticals Inc.
2.1.1 Acadia Pharmaceuticals Inc. Details
2.1.2 Acadia Pharmaceuticals Inc. Major Business
2.1.3 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.1.4 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Acadia Pharmaceuticals Inc. Recent Developments and Future Plans
2.2 Kyowa Kirin
2.2.1 Kyowa Kirin Details
2.2.2 Kyowa Kirin Major Business
2.2.3 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.2.4 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Kyowa Kirin Recent Developments and Future Plans
2.3 Supernus Pharmaceuticals
2.3.1 Supernus Pharmaceuticals Details
2.3.2 Supernus Pharmaceuticals Major Business
2.3.3 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.3.4 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Supernus Pharmaceuticals Recent Developments and Future Plans
2.4 UCB
2.4.1 UCB Details
2.4.2 UCB Major Business
2.4.3 UCB Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.4.4 UCB Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 UCB Recent Developments and Future Plans
2.5 Sumitomo Pharma
2.5.1 Sumitomo Pharma Details
2.5.2 Sumitomo Pharma Major Business
2.5.3 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.5.4 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Sumitomo Pharma Recent Developments and Future Plans
2.6 Biogen
2.6.1 Biogen Details
2.6.2 Biogen Major Business
2.6.3 Biogen Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.6.4 Biogen Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Biogen Recent Developments and Future Plans
2.7 Eisai Inc.
2.7.1 Eisai Inc. Details
2.7.2 Eisai Inc. Major Business
2.7.3 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.7.4 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Eisai Inc. Recent Developments and Future Plans
2.8 Eli Lilly
2.8.1 Eli Lilly Details
2.8.2 Eli Lilly Major Business
2.8.3 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.8.4 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Eli Lilly Recent Developments and Future Plans
2.9 Green Valley
2.9.1 Green Valley Details
2.9.2 Green Valley Major Business
2.9.3 Green Valley Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.9.4 Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Green Valley Recent Developments and Future Plans
2.10 NOVARTIS
2.10.1 NOVARTIS Details
2.10.2 NOVARTIS Major Business
2.10.3 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.10.4 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 NOVARTIS Recent Developments and Future Plans
2.11 Bristol-Myers Squibb
2.11.1 Bristol-Myers Squibb Details
2.11.2 Bristol-Myers Squibb Major Business
2.11.3 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.11.4 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.12 Janssen
2.12.1 Janssen Details
2.12.2 Janssen Major Business
2.12.3 Janssen Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.12.4 Janssen Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Janssen Recent Developments and Future Plans
2.13 Sanofi
2.13.1 Sanofi Details
2.13.2 Sanofi Major Business
2.13.3 Sanofi Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.13.4 Sanofi Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Sanofi Recent Developments and Future Plans
2.14 Roche
2.14.1 Roche Details
2.14.2 Roche Major Business
2.14.3 Roche Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.14.4 Roche Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Roche Recent Developments and Future Plans
2.15 Neurocrine
2.15.1 Neurocrine Details
2.15.2 Neurocrine Major Business
2.15.3 Neurocrine Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.15.4 Neurocrine Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Neurocrine Recent Developments and Future Plans
2.16 Lundbeck
2.16.1 Lundbeck Details
2.16.2 Lundbeck Major Business
2.16.3 Lundbeck Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.16.4 Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Lundbeck Recent Developments and Future Plans
2.17 Teva
2.17.1 Teva Details
2.17.2 Teva Major Business
2.17.3 Teva Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.17.4 Teva Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Teva Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Targeted Drugs for Neurodegenerative Diseases Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Targeted Drugs for Neurodegenerative Diseases by Company Revenue
3.2.2 Top 3 Targeted Drugs for Neurodegenerative Diseases Players Market Share in 2025
3.2.3 Top 6 Targeted Drugs for Neurodegenerative Diseases Players Market Share in 2025
3.3 Targeted Drugs for Neurodegenerative Diseases Market: Overall Company Footprint Analysis
3.3.1 Targeted Drugs for Neurodegenerative Diseases Market: Region Footprint
3.3.2 Targeted Drugs for Neurodegenerative Diseases Market: Company Product Type Footprint
3.3.3 Targeted Drugs for Neurodegenerative Diseases Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Targeted Drugs for Neurodegenerative Diseases Consumption Value and Market Share by Type (2021-2026)
4.2 Global Targeted Drugs for Neurodegenerative Diseases Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Application (2021-2026)
5.2 Global Targeted Drugs for Neurodegenerative Diseases Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2032)
6.2 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2032)
6.3 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country
6.3.1 North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2032)
6.3.2 United States Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
6.3.3 Canada Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
6.3.4 Mexico Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2032)
7.2 Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2032)
7.3 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country
7.3.1 Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2032)
7.3.2 Germany Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
7.3.3 France Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
7.3.5 Russia Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
7.3.6 Italy Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Region
8.3.1 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Region (2021-2032)
8.3.2 China Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
8.3.3 Japan Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
8.3.4 South Korea Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
8.3.5 India Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
8.3.7 Australia Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2032)
9.2 South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2032)
9.3 South America Targeted Drugs for Neurodegenerative Diseases Market Size by Country
9.3.1 South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2032)
9.3.2 Brazil Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
9.3.3 Argentina Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country
10.3.1 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2032)
10.3.2 Turkey Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
10.3.4 UAE Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Targeted Drugs for Neurodegenerative Diseases Market Drivers
11.2 Targeted Drugs for Neurodegenerative Diseases Market Restraints
11.3 Targeted Drugs for Neurodegenerative Diseases Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Targeted Drugs for Neurodegenerative Diseases Industry Chain
12.2 Targeted Drugs for Neurodegenerative Diseases Upstream Analysis
12.3 Targeted Drugs for Neurodegenerative Diseases Midstream Analysis
12.4 Targeted Drugs for Neurodegenerative Diseases Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Targeted Drugs for Neurodegenerative Diseases by Type
1.3.1 Overview: Global Targeted Drugs for Neurodegenerative Diseases Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Type in 2025
1.3.3 Injection
1.3.4 Oral
1.4 Global Targeted Drugs for Neurodegenerative Diseases Market by Application
1.4.1 Overview: Global Targeted Drugs for Neurodegenerative Diseases Market Size by Application: 2021 Versus 2025 Versus 2032
1.4.2 Parkinson's Disease (PD)
1.4.3 Alzheimer's Disease (AD)
1.4.4 Huntington's Disease (HD)
1.4.5 Tardive Dyskinesia (TD)
1.4.6 Multiple Sclerosis (MS)
1.5 Global Targeted Drugs for Neurodegenerative Diseases Market Size & Forecast
1.6 Global Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast by Region
1.6.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region: 2021 VS 2025 VS 2032
1.6.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region, (2021-2032)
1.6.3 North America Targeted Drugs for Neurodegenerative Diseases Market Size and Prospect (2021-2032)
1.6.4 Europe Targeted Drugs for Neurodegenerative Diseases Market Size and Prospect (2021-2032)
1.6.5 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size and Prospect (2021-2032)
1.6.6 South America Targeted Drugs for Neurodegenerative Diseases Market Size and Prospect (2021-2032)
1.6.7 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Acadia Pharmaceuticals Inc.
2.1.1 Acadia Pharmaceuticals Inc. Details
2.1.2 Acadia Pharmaceuticals Inc. Major Business
2.1.3 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.1.4 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Acadia Pharmaceuticals Inc. Recent Developments and Future Plans
2.2 Kyowa Kirin
2.2.1 Kyowa Kirin Details
2.2.2 Kyowa Kirin Major Business
2.2.3 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.2.4 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Kyowa Kirin Recent Developments and Future Plans
2.3 Supernus Pharmaceuticals
2.3.1 Supernus Pharmaceuticals Details
2.3.2 Supernus Pharmaceuticals Major Business
2.3.3 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.3.4 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Supernus Pharmaceuticals Recent Developments and Future Plans
2.4 UCB
2.4.1 UCB Details
2.4.2 UCB Major Business
2.4.3 UCB Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.4.4 UCB Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 UCB Recent Developments and Future Plans
2.5 Sumitomo Pharma
2.5.1 Sumitomo Pharma Details
2.5.2 Sumitomo Pharma Major Business
2.5.3 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.5.4 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Sumitomo Pharma Recent Developments and Future Plans
2.6 Biogen
2.6.1 Biogen Details
2.6.2 Biogen Major Business
2.6.3 Biogen Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.6.4 Biogen Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Biogen Recent Developments and Future Plans
2.7 Eisai Inc.
2.7.1 Eisai Inc. Details
2.7.2 Eisai Inc. Major Business
2.7.3 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.7.4 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Eisai Inc. Recent Developments and Future Plans
2.8 Eli Lilly
2.8.1 Eli Lilly Details
2.8.2 Eli Lilly Major Business
2.8.3 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.8.4 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Eli Lilly Recent Developments and Future Plans
2.9 Green Valley
2.9.1 Green Valley Details
2.9.2 Green Valley Major Business
2.9.3 Green Valley Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.9.4 Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Green Valley Recent Developments and Future Plans
2.10 NOVARTIS
2.10.1 NOVARTIS Details
2.10.2 NOVARTIS Major Business
2.10.3 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.10.4 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 NOVARTIS Recent Developments and Future Plans
2.11 Bristol-Myers Squibb
2.11.1 Bristol-Myers Squibb Details
2.11.2 Bristol-Myers Squibb Major Business
2.11.3 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.11.4 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.12 Janssen
2.12.1 Janssen Details
2.12.2 Janssen Major Business
2.12.3 Janssen Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.12.4 Janssen Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Janssen Recent Developments and Future Plans
2.13 Sanofi
2.13.1 Sanofi Details
2.13.2 Sanofi Major Business
2.13.3 Sanofi Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.13.4 Sanofi Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Sanofi Recent Developments and Future Plans
2.14 Roche
2.14.1 Roche Details
2.14.2 Roche Major Business
2.14.3 Roche Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.14.4 Roche Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Roche Recent Developments and Future Plans
2.15 Neurocrine
2.15.1 Neurocrine Details
2.15.2 Neurocrine Major Business
2.15.3 Neurocrine Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.15.4 Neurocrine Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Neurocrine Recent Developments and Future Plans
2.16 Lundbeck
2.16.1 Lundbeck Details
2.16.2 Lundbeck Major Business
2.16.3 Lundbeck Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.16.4 Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Lundbeck Recent Developments and Future Plans
2.17 Teva
2.17.1 Teva Details
2.17.2 Teva Major Business
2.17.3 Teva Targeted Drugs for Neurodegenerative Diseases Product and Solutions
2.17.4 Teva Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Teva Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Targeted Drugs for Neurodegenerative Diseases Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Targeted Drugs for Neurodegenerative Diseases by Company Revenue
3.2.2 Top 3 Targeted Drugs for Neurodegenerative Diseases Players Market Share in 2025
3.2.3 Top 6 Targeted Drugs for Neurodegenerative Diseases Players Market Share in 2025
3.3 Targeted Drugs for Neurodegenerative Diseases Market: Overall Company Footprint Analysis
3.3.1 Targeted Drugs for Neurodegenerative Diseases Market: Region Footprint
3.3.2 Targeted Drugs for Neurodegenerative Diseases Market: Company Product Type Footprint
3.3.3 Targeted Drugs for Neurodegenerative Diseases Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Targeted Drugs for Neurodegenerative Diseases Consumption Value and Market Share by Type (2021-2026)
4.2 Global Targeted Drugs for Neurodegenerative Diseases Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Application (2021-2026)
5.2 Global Targeted Drugs for Neurodegenerative Diseases Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2032)
6.2 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2032)
6.3 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country
6.3.1 North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2032)
6.3.2 United States Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
6.3.3 Canada Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
6.3.4 Mexico Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2032)
7.2 Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2032)
7.3 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country
7.3.1 Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2032)
7.3.2 Germany Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
7.3.3 France Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
7.3.5 Russia Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
7.3.6 Italy Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Region
8.3.1 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Region (2021-2032)
8.3.2 China Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
8.3.3 Japan Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
8.3.4 South Korea Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
8.3.5 India Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
8.3.7 Australia Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2032)
9.2 South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2032)
9.3 South America Targeted Drugs for Neurodegenerative Diseases Market Size by Country
9.3.1 South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2032)
9.3.2 Brazil Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
9.3.3 Argentina Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country
10.3.1 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2032)
10.3.2 Turkey Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
10.3.4 UAE Targeted Drugs for Neurodegenerative Diseases Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Targeted Drugs for Neurodegenerative Diseases Market Drivers
11.2 Targeted Drugs for Neurodegenerative Diseases Market Restraints
11.3 Targeted Drugs for Neurodegenerative Diseases Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Targeted Drugs for Neurodegenerative Diseases Industry Chain
12.2 Targeted Drugs for Neurodegenerative Diseases Upstream Analysis
12.3 Targeted Drugs for Neurodegenerative Diseases Midstream Analysis
12.4 Targeted Drugs for Neurodegenerative Diseases Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value by Region (2021-2026) & (USD Million)
Table 4. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value by Region (2027-2032) & (USD Million)
Table 5. Acadia Pharmaceuticals Inc. Company Information, Head Office, and Major Competitors
Table 6. Acadia Pharmaceuticals Inc. Major Business
Table 7. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 8. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Acadia Pharmaceuticals Inc. Recent Developments and Future Plans
Table 10. Kyowa Kirin Company Information, Head Office, and Major Competitors
Table 11. Kyowa Kirin Major Business
Table 12. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 13. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Kyowa Kirin Recent Developments and Future Plans
Table 15. Supernus Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 16. Supernus Pharmaceuticals Major Business
Table 17. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 18. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. UCB Company Information, Head Office, and Major Competitors
Table 20. UCB Major Business
Table 21. UCB Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 22. UCB Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 23. UCB Recent Developments and Future Plans
Table 24. Sumitomo Pharma Company Information, Head Office, and Major Competitors
Table 25. Sumitomo Pharma Major Business
Table 26. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 27. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 28. Sumitomo Pharma Recent Developments and Future Plans
Table 29. Biogen Company Information, Head Office, and Major Competitors
Table 30. Biogen Major Business
Table 31. Biogen Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 32. Biogen Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 33. Biogen Recent Developments and Future Plans
Table 34. Eisai Inc. Company Information, Head Office, and Major Competitors
Table 35. Eisai Inc. Major Business
Table 36. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 37. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 38. Eisai Inc. Recent Developments and Future Plans
Table 39. Eli Lilly Company Information, Head Office, and Major Competitors
Table 40. Eli Lilly Major Business
Table 41. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 42. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 43. Eli Lilly Recent Developments and Future Plans
Table 44. Green Valley Company Information, Head Office, and Major Competitors
Table 45. Green Valley Major Business
Table 46. Green Valley Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 47. Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 48. Green Valley Recent Developments and Future Plans
Table 49. NOVARTIS Company Information, Head Office, and Major Competitors
Table 50. NOVARTIS Major Business
Table 51. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 52. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 53. NOVARTIS Recent Developments and Future Plans
Table 54. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
Table 55. Bristol-Myers Squibb Major Business
Table 56. Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 57. Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 58. Bristol-Myers Squibb Recent Developments and Future Plans
Table 59. Janssen Company Information, Head Office, and Major Competitors
Table 60. Janssen Major Business
Table 61. Janssen Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 62. Janssen Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 63. Janssen Recent Developments and Future Plans
Table 64. Sanofi Company Information, Head Office, and Major Competitors
Table 65. Sanofi Major Business
Table 66. Sanofi Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 67. Sanofi Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 68. Sanofi Recent Developments and Future Plans
Table 69. Roche Company Information, Head Office, and Major Competitors
Table 70. Roche Major Business
Table 71. Roche Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 72. Roche Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 73. Roche Recent Developments and Future Plans
Table 74. Neurocrine Company Information, Head Office, and Major Competitors
Table 75. Neurocrine Major Business
Table 76. Neurocrine Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 77. Neurocrine Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 78. Neurocrine Recent Developments and Future Plans
Table 79. Lundbeck Company Information, Head Office, and Major Competitors
Table 80. Lundbeck Major Business
Table 81. Lundbeck Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 82. Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 83. Lundbeck Recent Developments and Future Plans
Table 84. Teva Company Information, Head Office, and Major Competitors
Table 85. Teva Major Business
Table 86. Teva Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 87. Teva Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 88. Teva Recent Developments and Future Plans
Table 89. Global Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million) by Players (2021-2026)
Table 90. Global Targeted Drugs for Neurodegenerative Diseases Revenue Share by Players (2021-2026)
Table 91. Breakdown of Targeted Drugs for Neurodegenerative Diseases by Company Type (Tier 1, Tier 2, and Tier 3)
Table 92. Market Position of Players in Targeted Drugs for Neurodegenerative Diseases, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 93. Head Office of Key Targeted Drugs for Neurodegenerative Diseases Players
Table 94. Targeted Drugs for Neurodegenerative Diseases Market: Company Product Type Footprint
Table 95. Targeted Drugs for Neurodegenerative Diseases Market: Company Product Application Footprint
Table 96. Targeted Drugs for Neurodegenerative Diseases New Market Entrants and Barriers to Market Entry
Table 97. Targeted Drugs for Neurodegenerative Diseases Mergers, Acquisition, Agreements, and Collaborations
Table 98. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value (USD Million) by Type (2021-2026)
Table 99. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Share by Type (2021-2026)
Table 100. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Forecast by Type (2027-2032)
Table 101. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2026)
Table 102. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Forecast by Application (2027-2032)
Table 103. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 104. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 105. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 106. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 107. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2026) & (USD Million)
Table 108. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2027-2032) & (USD Million)
Table 109. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 110. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 111. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 112. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 113. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2026) & (USD Million)
Table 114. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2027-2032) & (USD Million)
Table 115. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 116. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 117. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 118. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 119. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Region (2021-2026) & (USD Million)
Table 120. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Region (2027-2032) & (USD Million)
Table 121. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 122. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 123. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 124. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 125. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2026) & (USD Million)
Table 126. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2027-2032) & (USD Million)
Table 127. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 128. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 129. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 130. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 131. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2026) & (USD Million)
Table 132. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2027-2032) & (USD Million)
Table 133. Global Key Players of Targeted Drugs for Neurodegenerative Diseases Upstream (Raw Materials)
Table 134. Global Targeted Drugs for Neurodegenerative Diseases Typical Customers
Table 1. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value by Region (2021-2026) & (USD Million)
Table 4. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value by Region (2027-2032) & (USD Million)
Table 5. Acadia Pharmaceuticals Inc. Company Information, Head Office, and Major Competitors
Table 6. Acadia Pharmaceuticals Inc. Major Business
Table 7. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 8. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Acadia Pharmaceuticals Inc. Recent Developments and Future Plans
Table 10. Kyowa Kirin Company Information, Head Office, and Major Competitors
Table 11. Kyowa Kirin Major Business
Table 12. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 13. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Kyowa Kirin Recent Developments and Future Plans
Table 15. Supernus Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 16. Supernus Pharmaceuticals Major Business
Table 17. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 18. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. UCB Company Information, Head Office, and Major Competitors
Table 20. UCB Major Business
Table 21. UCB Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 22. UCB Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 23. UCB Recent Developments and Future Plans
Table 24. Sumitomo Pharma Company Information, Head Office, and Major Competitors
Table 25. Sumitomo Pharma Major Business
Table 26. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 27. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 28. Sumitomo Pharma Recent Developments and Future Plans
Table 29. Biogen Company Information, Head Office, and Major Competitors
Table 30. Biogen Major Business
Table 31. Biogen Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 32. Biogen Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 33. Biogen Recent Developments and Future Plans
Table 34. Eisai Inc. Company Information, Head Office, and Major Competitors
Table 35. Eisai Inc. Major Business
Table 36. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 37. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 38. Eisai Inc. Recent Developments and Future Plans
Table 39. Eli Lilly Company Information, Head Office, and Major Competitors
Table 40. Eli Lilly Major Business
Table 41. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 42. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 43. Eli Lilly Recent Developments and Future Plans
Table 44. Green Valley Company Information, Head Office, and Major Competitors
Table 45. Green Valley Major Business
Table 46. Green Valley Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 47. Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 48. Green Valley Recent Developments and Future Plans
Table 49. NOVARTIS Company Information, Head Office, and Major Competitors
Table 50. NOVARTIS Major Business
Table 51. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 52. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 53. NOVARTIS Recent Developments and Future Plans
Table 54. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
Table 55. Bristol-Myers Squibb Major Business
Table 56. Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 57. Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 58. Bristol-Myers Squibb Recent Developments and Future Plans
Table 59. Janssen Company Information, Head Office, and Major Competitors
Table 60. Janssen Major Business
Table 61. Janssen Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 62. Janssen Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 63. Janssen Recent Developments and Future Plans
Table 64. Sanofi Company Information, Head Office, and Major Competitors
Table 65. Sanofi Major Business
Table 66. Sanofi Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 67. Sanofi Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 68. Sanofi Recent Developments and Future Plans
Table 69. Roche Company Information, Head Office, and Major Competitors
Table 70. Roche Major Business
Table 71. Roche Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 72. Roche Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 73. Roche Recent Developments and Future Plans
Table 74. Neurocrine Company Information, Head Office, and Major Competitors
Table 75. Neurocrine Major Business
Table 76. Neurocrine Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 77. Neurocrine Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 78. Neurocrine Recent Developments and Future Plans
Table 79. Lundbeck Company Information, Head Office, and Major Competitors
Table 80. Lundbeck Major Business
Table 81. Lundbeck Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 82. Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 83. Lundbeck Recent Developments and Future Plans
Table 84. Teva Company Information, Head Office, and Major Competitors
Table 85. Teva Major Business
Table 86. Teva Targeted Drugs for Neurodegenerative Diseases Product and Solutions
Table 87. Teva Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 88. Teva Recent Developments and Future Plans
Table 89. Global Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million) by Players (2021-2026)
Table 90. Global Targeted Drugs for Neurodegenerative Diseases Revenue Share by Players (2021-2026)
Table 91. Breakdown of Targeted Drugs for Neurodegenerative Diseases by Company Type (Tier 1, Tier 2, and Tier 3)
Table 92. Market Position of Players in Targeted Drugs for Neurodegenerative Diseases, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 93. Head Office of Key Targeted Drugs for Neurodegenerative Diseases Players
Table 94. Targeted Drugs for Neurodegenerative Diseases Market: Company Product Type Footprint
Table 95. Targeted Drugs for Neurodegenerative Diseases Market: Company Product Application Footprint
Table 96. Targeted Drugs for Neurodegenerative Diseases New Market Entrants and Barriers to Market Entry
Table 97. Targeted Drugs for Neurodegenerative Diseases Mergers, Acquisition, Agreements, and Collaborations
Table 98. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value (USD Million) by Type (2021-2026)
Table 99. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Share by Type (2021-2026)
Table 100. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Forecast by Type (2027-2032)
Table 101. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2026)
Table 102. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Forecast by Application (2027-2032)
Table 103. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 104. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 105. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 106. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 107. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2026) & (USD Million)
Table 108. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2027-2032) & (USD Million)
Table 109. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 110. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 111. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 112. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 113. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2026) & (USD Million)
Table 114. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2027-2032) & (USD Million)
Table 115. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 116. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 117. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 118. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 119. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Region (2021-2026) & (USD Million)
Table 120. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value by Region (2027-2032) & (USD Million)
Table 121. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 122. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 123. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 124. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 125. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2026) & (USD Million)
Table 126. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2027-2032) & (USD Million)
Table 127. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 128. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 129. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 130. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 131. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2021-2026) & (USD Million)
Table 132. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value by Country (2027-2032) & (USD Million)
Table 133. Global Key Players of Targeted Drugs for Neurodegenerative Diseases Upstream (Raw Materials)
Table 134. Global Targeted Drugs for Neurodegenerative Diseases Typical Customers
LIST OF FIGURES
Figure 1. Targeted Drugs for Neurodegenerative Diseases Picture
Figure 2. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Type in 2025
Figure 4. Injection
Figure 5. Oral
Figure 6. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 7. Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Application in 2025
Figure 8. Parkinson's Disease (PD) Picture
Figure 9. Alzheimer's Disease (AD) Picture
Figure 10. Huntington's Disease (HD) Picture
Figure 11. Tardive Dyskinesia (TD) Picture
Figure 12. Multiple Sclerosis (MS) Picture
Figure 13. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 14. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 15. Global Market Targeted Drugs for Neurodegenerative Diseases Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 16. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Region (2021-2032)
Figure 17. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Region in 2025
Figure 18. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 20. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 21. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 22. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 23. Company Three Recent Developments and Future Plans
Figure 24. Global Targeted Drugs for Neurodegenerative Diseases Revenue Share by Players in 2025
Figure 25. Targeted Drugs for Neurodegenerative Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 26. Market Share of Targeted Drugs for Neurodegenerative Diseases by Player Revenue in 2025
Figure 27. Top 3 Targeted Drugs for Neurodegenerative Diseases Players Market Share in 2025
Figure 28. Top 6 Targeted Drugs for Neurodegenerative Diseases Players Market Share in 2025
Figure 29. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Share by Type (2021-2026)
Figure 30. Global Targeted Drugs for Neurodegenerative Diseases Market Share Forecast by Type (2027-2032)
Figure 31. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Share by Application (2021-2026)
Figure 32. Global Targeted Drugs for Neurodegenerative Diseases Market Share Forecast by Application (2027-2032)
Figure 33. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Type (2021-2032)
Figure 34. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Application (2021-2032)
Figure 35. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Country (2021-2032)
Figure 36. United States Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 37. Canada Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 38. Mexico Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 39. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Type (2021-2032)
Figure 40. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Application (2021-2032)
Figure 41. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Country (2021-2032)
Figure 42. Germany Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 43. France Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 44. United Kingdom Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 45. Russia Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 46. Italy Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 47. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Type (2021-2032)
Figure 48. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Application (2021-2032)
Figure 49. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Region (2021-2032)
Figure 50. China Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 51. Japan Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 52. South Korea Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 53. India Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 54. Southeast Asia Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 55. Australia Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 56. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Type (2021-2032)
Figure 57. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Application (2021-2032)
Figure 58. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Country (2021-2032)
Figure 59. Brazil Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 60. Argentina Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 61. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Type (2021-2032)
Figure 62. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Application (2021-2032)
Figure 63. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Country (2021-2032)
Figure 64. Turkey Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 65. Saudi Arabia Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 66. UAE Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 67. Targeted Drugs for Neurodegenerative Diseases Market Drivers
Figure 68. Targeted Drugs for Neurodegenerative Diseases Market Restraints
Figure 69. Targeted Drugs for Neurodegenerative Diseases Market Trends
Figure 70. Porters Five Forces Analysis
Figure 71. Targeted Drugs for Neurodegenerative Diseases Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
Figure 1. Targeted Drugs for Neurodegenerative Diseases Picture
Figure 2. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Type in 2025
Figure 4. Injection
Figure 5. Oral
Figure 6. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 7. Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Application in 2025
Figure 8. Parkinson's Disease (PD) Picture
Figure 9. Alzheimer's Disease (AD) Picture
Figure 10. Huntington's Disease (HD) Picture
Figure 11. Tardive Dyskinesia (TD) Picture
Figure 12. Multiple Sclerosis (MS) Picture
Figure 13. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 14. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 15. Global Market Targeted Drugs for Neurodegenerative Diseases Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 16. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Region (2021-2032)
Figure 17. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Region in 2025
Figure 18. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 20. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 21. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 22. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 23. Company Three Recent Developments and Future Plans
Figure 24. Global Targeted Drugs for Neurodegenerative Diseases Revenue Share by Players in 2025
Figure 25. Targeted Drugs for Neurodegenerative Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 26. Market Share of Targeted Drugs for Neurodegenerative Diseases by Player Revenue in 2025
Figure 27. Top 3 Targeted Drugs for Neurodegenerative Diseases Players Market Share in 2025
Figure 28. Top 6 Targeted Drugs for Neurodegenerative Diseases Players Market Share in 2025
Figure 29. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Share by Type (2021-2026)
Figure 30. Global Targeted Drugs for Neurodegenerative Diseases Market Share Forecast by Type (2027-2032)
Figure 31. Global Targeted Drugs for Neurodegenerative Diseases Consumption Value Share by Application (2021-2026)
Figure 32. Global Targeted Drugs for Neurodegenerative Diseases Market Share Forecast by Application (2027-2032)
Figure 33. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Type (2021-2032)
Figure 34. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Application (2021-2032)
Figure 35. North America Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Country (2021-2032)
Figure 36. United States Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 37. Canada Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 38. Mexico Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 39. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Type (2021-2032)
Figure 40. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Application (2021-2032)
Figure 41. Europe Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Country (2021-2032)
Figure 42. Germany Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 43. France Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 44. United Kingdom Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 45. Russia Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 46. Italy Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 47. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Type (2021-2032)
Figure 48. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Application (2021-2032)
Figure 49. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Region (2021-2032)
Figure 50. China Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 51. Japan Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 52. South Korea Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 53. India Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 54. Southeast Asia Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 55. Australia Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 56. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Type (2021-2032)
Figure 57. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Application (2021-2032)
Figure 58. South America Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Country (2021-2032)
Figure 59. Brazil Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 60. Argentina Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 61. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Type (2021-2032)
Figure 62. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Application (2021-2032)
Figure 63. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Consumption Value Market Share by Country (2021-2032)
Figure 64. Turkey Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 65. Saudi Arabia Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 66. UAE Targeted Drugs for Neurodegenerative Diseases Consumption Value (2021-2032) & (USD Million)
Figure 67. Targeted Drugs for Neurodegenerative Diseases Market Drivers
Figure 68. Targeted Drugs for Neurodegenerative Diseases Market Restraints
Figure 69. Targeted Drugs for Neurodegenerative Diseases Market Trends
Figure 70. Porters Five Forces Analysis
Figure 71. Targeted Drugs for Neurodegenerative Diseases Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
